Skip to content

Study · In vitro (cells) · 2001

4 results

Gene construction, expression, and characterization of double-copy truncated form of human insulin-like growth factor I.

Sun HY, Liu XH, Liang SW

Acta pharmacologica Sinica1 Jul 2001

PMID11749827 (opens in a new tab)PepBankPUB-11749827
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In MTT assays, gelfiltered des(1‑3)IGF-I showed about 77% of standard IGF-I bioactivity at the same concentration.

    In plain wordsIn lab tests, purified des(1‑3)IGF-I had about 77% of standard IGF-I activity at the same concentration.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseRelative bioactivity
    Study

    n: not reported in source

    MTT bioactivity assay
    Comparator
    Standard IGF-I at the same concentration
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Relative bioactivity
    ≈ 77%
    standard IGF-I at same concentration

    Source sentences

    Summary
    The bioactivity of des(1-3)IGF-I after gelfiltration was about 77 % of standard IGF-I at the same concentration.
    2 context sentences
    Summary · context
    The second copy of des(1-3)IGF-I gene was inserted into the previously constructed pExSec1/IGF-I to form a pExSec1/2(IGF-I) expression plasmid, then the plasmid was transformed into a protease-deficient E coli strain BL21(DE3).
    Summary · context
    The bioactivity of the preliminarily purified protein was tested by MTT method and compared with standard IGF-I.

Studies that did not test the peptide alone3

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Other

    In engineered E coli, the double-copy construct expressed des(1‑3)IGF-I at up to 20% of soluble protein versus 12% with one copy.

    In plain wordsIn lab tests, a double-copy construct produced more des(1‑3)IGF-I than a single-copy construct.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseRecombinant peptide expression
    Study

    Escherichia colin: not reported in source

    BL21(DE3) expression system
    Comparator
    Single-copy expression plasmid
    Outcome group
    Product quality and purity · Pharmacology

    Measurements

    Soluble protein fraction
    20%
    up to; double-copy construct
    Soluble protein fraction
    12%
    single-copy construct

    Source sentences

    Summary
    The amount of des(1-3)IGF-I expressed by pExSec1/2(IGF-I) reached up to 20 % of the total soluble bacterial protein, which was higher than the amount (12 %) expressed by a single copy of pExSec1/IGF-I gene.
    2 context sentences
    Summary · context
    The second copy of des(1-3)IGF-I gene was inserted into the previously constructed pExSec1/IGF-I to form a pExSec1/2(IGF-I) expression plasmid, then the plasmid was transformed into a protease-deficient E coli strain BL21(DE3).
    Summary · context
    The bioactivity of the preliminarily purified protein was tested by MTT method and compared with standard IGF-I.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Other

    In recombinant protein purification, des(1‑3)IGF-I purity reached 49% after ultrafiltration.

    In plain wordsIn lab tests, des(1‑3)IGF-I purity reached 49% after ultrafiltration.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicablePurity after ultrafiltration
    Study

    Escherichia colin: not reported in source

    Recombinant des(1-3)IGF-I purification by ultrafiltration
    Outcome group
    Product quality and purity · Pharmacology

    Measurements

    Purity
    49%
    after ultrafiltration

    Source sentences

    Summary
    The purity of recombinant des(1-3)IGF-I reached 49 % and 82 % after ultrafiltration and gelfiltration.
    2 context sentences
    Summary · context
    The second copy of des(1-3)IGF-I gene was inserted into the previously constructed pExSec1/IGF-I to form a pExSec1/2(IGF-I) expression plasmid, then the plasmid was transformed into a protease-deficient E coli strain BL21(DE3).
    Summary · context
    The bioactivity of the preliminarily purified protein was tested by MTT method and compared with standard IGF-I.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  3. 04LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Other

    In recombinant protein purification, des(1‑3)IGF-I purity reached 82% after gelfiltration.

    In plain wordsIn lab tests, des(1‑3)IGF-I purity reached 82% after gelfiltration.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicablePurity after gelfiltration
    Study

    Escherichia colin: not reported in source

    Recombinant des(1-3)IGF-I purification by gelfiltration
    Outcome group
    Product quality and purity · Pharmacology

    Measurements

    Purity
    82%
    after gelfiltration

    Source sentences

    Summary
    The purity of recombinant des(1-3)IGF-I reached 49 % and 82 % after ultrafiltration and gelfiltration.
    2 context sentences
    Summary · context
    The second copy of des(1-3)IGF-I gene was inserted into the previously constructed pExSec1/IGF-I to form a pExSec1/2(IGF-I) expression plasmid, then the plasmid was transformed into a protease-deficient E coli strain BL21(DE3).
    Summary · context
    The bioactivity of the preliminarily purified protein was tested by MTT method and compared with standard IGF-I.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.